China's central bank to further erode role of medium-term loan rate
China's central bank said it will change the way it sells its medium-term loans, a move that market participants say may ...
Panama ports deal: eyebrows raised over Hong Kong’s Richard Li in Beijing, observers say
The appearance of the younger son of Hong Kong billionaire Li Ka-shing at a high-profile summit in Beijing on the weekend ...
Renewed civil war over Taiwan may be option for Beijing: mainland researcher
Article in journal from key Taiwan-related think tank also suggests ‘direct governance during wartime’, followed by ...
How China’s massive defence spending doesn’t ensure strategic security for it
Beijing has long perfected the art of budgetary camouflage. Significant sums are routinely hidden off the official balance ...
China.org.cn2d
Chinese vice premier encourages multinational companies to expand investment in China
China will continue to open up at a higher level, and welcomes multinational companies to expand investment in China to ...
Beijing will keep Hong Kong ‘free and open’ for business, Euro chamber told
Beijing’s point man on Hong Kong affairs has underscored the central government’s determination to maintain the city’s “free ...
Fleeing Hong Kong Wasn’t Enough
China’s war on dissidents comes to the United Kingdom.
Pakistan Today14h
China, India hold 33rd meeting of working mechanism on border affairs
BEIJING: China and India on Tuesday held their latest round of meetings to exchange views on relevant issues in border areas ...
China Daily Global Edition4d
Beijing reveals blossom sightseeing spots
The Beijing Municipal Bureau of Culture and Tourism announced the locations of the city's Top 10 Spring Flower Viewing Spots ...
The Diplomat16h
No Aid, All Investments: The Future of Chinese Engagement in Kazakhstan
With U.S. aid diminished, it seems unlikely that China will fill the gap. Beijing favors investments in infrastructure over ...
Ascentage Pharma to Present Five Preclinical Studies from Innovative Pipeline at American Association of Cancer Research (AACR) Annual Meeting 2025
The data to be presented encompasses five of the company’s novel drug candidates: BCR-ABL tyrosine kinase inhibitor olverembatinib (HQP1351), Bcl-2 inhibitor lisaftoclax (APG-2575), FAK/ALK/ROS1 ...